Joel Greenblatt's GILD Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 345,897 shares of Gilead Sciences, Inc. (GILD) worth $38.39 M, representing 0.17% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 345,239 shares. Largest reduction occurred in Q1 2019, reducing 314,073 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +466,853 | New Buy | 466,853 | $82.91 |
| Q3 2014 | +197,370 | Add 42.28% | 664,223 | $106.45 |
| Q4 2014 | +345,239 | Add 51.98% | 1.01 M | $94.26 |
| Q1 2015 | +98,270 | Add 9.73% | 1.11 M | $98.13 |
| Q2 2015 | -39,604 | Reduce 3.58% | 1.07 M | $117.08 |
| Q3 2015 | -131,146 | Reduce 12.28% | 936,982 | $98.19 |
| Q4 2015 | -62,736 | Reduce 6.70% | 874,246 | $101.19 |
| Q1 2016 | +93,396 | Add 10.68% | 967,642 | $91.86 |
| Q2 2016 | +48,500 | Add 5.01% | 1.02 M | $83.42 |
| Q3 2016 | -92,608 | Reduce 9.11% | 923,534 | $79.12 |
| Q4 2016 | +101,669 | Add 11.01% | 1.03 M | $71.61 |
| Q1 2017 | +186,833 | Add 18.22% | 1.21 M | $67.92 |
| Q2 2017 | -248,315 | Reduce 20.49% | 963,721 | $70.78 |
| Q3 2017 | -267,099 | Reduce 27.72% | 696,622 | $81.02 |
| Q4 2017 | -31,830 | Reduce 4.57% | 664,792 | $71.64 |
| Q1 2018 | -127,490 | Reduce 19.18% | 537,302 | $75.39 |
| Q2 2018 | -121,051 | Reduce 22.53% | 416,251 | $70.84 |
| Q3 2018 | -56,012 | Reduce 13.46% | 360,239 | $77.21 |
| Q4 2018 | +193,250 | Add 53.64% | 553,489 | $62.55 |
| Q1 2019 | -314,073 | Reduce 56.74% | 239,416 | $65.01 |
| Q2 2019 | +44,776 | Add 18.70% | 284,192 | $67.56 |
| Q3 2019 | +178,621 | Add 62.85% | 462,813 | $63.38 |
| Q4 2019 | -211,763 | Reduce 45.76% | 251,050 | $64.98 |
| Q1 2020 | -94,403 | Reduce 37.60% | 156,647 | $74.76 |
| Q2 2020 | -65,368 | Reduce 41.73% | 91,279 | $76.94 |
| Q3 2020 | -25,000 | Reduce 27.39% | 66,279 | $63.19 |
| Q4 2020 | +81,414 | Add 122.84% | 147,693 | $58.26 |
| Q1 2021 | -45,359 | Reduce 30.71% | 102,334 | $64.63 |
| Q2 2021 | -9,504 | Reduce 9.29% | 92,830 | $68.86 |
| Q3 2021 | +24,187 | Add 26.06% | 117,017 | $69.85 |
| Q4 2021 | -31,662 | Reduce 27.06% | 85,355 | $72.61 |
| Q1 2022 | +18,160 | Add 21.28% | 103,515 | $59.45 |
| Q2 2022 | -10,651 | Reduce 10.29% | 92,864 | $61.81 |
| Q3 2022 | -13,887 | Reduce 14.95% | 78,977 | $61.69 |
| Q4 2022 | +345 | Add 0.44% | 79,322 | $85.85 |
| Q1 2023 | +20,404 | Add 25.72% | 99,726 | $82.97 |
| Q2 2023 | +11,277 | Add 11.31% | 111,003 | $77.07 |
| Q3 2023 | +68,646 | Add 61.84% | 179,649 | $74.94 |
| Q4 2023 | -84,227 | Reduce 46.88% | 95,422 | $81.01 |
| Q1 2024 | +52,866 | Add 55.40% | 148,288 | $73.25 |
| Q2 2024 | +133,164 | Add 89.80% | 281,452 | $68.61 |
| Q3 2024 | -26,284 | Reduce 9.34% | 255,168 | $83.84 |
| Q4 2024 | +873 | Add 0.34% | 256,041 | $92.37 |
| Q1 2025 | -5,047 | Reduce 1.97% | 250,994 | $112.05 |
| Q2 2025 | +31,202 | Add 12.43% | 282,196 | $110.87 |
| Q3 2025 | +63,701 | Add 22.57% | 345,897 | $111.00 |
Joel Greenblatt's Gilead Sciences Investment FAQs
Joel Greenblatt first purchased Gilead Sciences, Inc. (GILD) in Q2 2014, acquiring 466,853 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Gilead Sciences, Inc. (GILD) for 46 quarters since Q2 2014.
Joel Greenblatt's largest addition to Gilead Sciences, Inc. (GILD) was in Q2 2014, adding 466,853 shares worth $38.71 M.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 345,897 shares of Gilead Sciences, Inc. (GILD), valued at approximately $38.39 M.
As of the Q3 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.17% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Gilead Sciences, Inc. (GILD) was 1,212,036 shares, as reported at the end of Q1 2017.